Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable ...

The reduction of hematocrit below 45% is a primary treatment ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.

Polycythemia vera (PV ... The goal is to lower your hematocrit level. Hematocrit is the percentage of red blood cells compared with the total amount of blood. You'll get this treatment once ...

Polycythemia vera (PV ... High numbers for hemoglobin, hematocrit, or blood cell count can all be signs of PV. The CBC takes only a few minutes. Your doctor puts a thin needle into your arm ...

Early statistics suggested that people with polycythemia vera were at a higher risk of dying from COVID-19, but more recent research suggests otherwise. However, it’s important to remember that ...

Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for men vs women. Treatment guidelines in PV currently recommend maintaining ...

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib ...

Ionis Pharmaceuticals licensed out its investigational antisense oligonucleotide sapablursen to Ono Pharmaceutical on Tuesday, giving the Japanese firm exclusive global rights to develop and ...

It gives Ionis cash to continue pursuing the development of wholly owned drugs, while giving Ono an experimental medicine that’s poised to offer an “attractive” option to doctors and patients who have ...

Clinical response rates were higher in patients with phlebotomy-dependent polycythemia vera who received rusfertide ... needs in patients with PV who are unable to achieve adequate hematocrit control ...